Immunohistochemical localization of metallothionein and p53 protein in pancreatic serous cystadenomas

  • Mariola Śliwińska-Mossoń
  • Halina Milnerowicz
  • Jerzy Rabczyński
  • Stanisław Milnerowicz
Open Access
Original Article



The objective of this study was to determine the expression levels of metallothionein (MT) and p53 protein, recognized neoplastic transformation markers, in pancreatic serous cystadenomas (SCA) and adenomocarcinomas.

Materials and Methods

Neoplastic pancreatic tissue was taken from 20 patients with diagnosed benign (SCA: 5 cases) or malignant tumors (adenomocarcinomas: 15 cases) and control pancreatic tissue from healthy persons who had died in car accidents. Sections were stained with hematoxylin-eosin. Immunohistochemical localization of MT and p53 protein was carried out by LSAB2-HRP using specific antibodies against MT and p53.


Metallothionein expression was observed only in the epithelial cells of the neoplastic tissue of SCAs. MT expression in the cystadenomas was weaker than in the healthy pancreatic tissue. No tissue was found with p53 protein expression. In the adenomocarcinomas, positive staining for MT was observed in 67% and p53 was positive in the carcinoma cells.


The weak MT expression and lack of p53 protein expression in pancreatic SCAs confirms the lack of local invasive potential of the neoplastic lesion. Increased expressions of MT and p53 were observed in the less differentiated tumors. Thus the expression of MT may be a potential prognostic marker for tumors.


serous cystadenoma adenomocarcinoma pancreas immunochemistry metallothionein p53 protein 





serous cystadenomas


periodic acid-Schiff


  1. Abdel-Mageed AB, Agrawal KC (1998) Activation of nuclear factor kappaB: potential role in metallothionein-mediated mitogenic response. Cancer Res 58: 2335–2338PubMedGoogle Scholar
  2. Alrefaie W, Katz MH, Easter DW et al (2004) Simultaneous serous cystadenoma of the pancreas and mucinous cystadenoma of the appendix. J Pancreas 5: 97–100Google Scholar
  3. Bartsch D, Bastian D, Barth P et al (1998) K-ras oncogene mutations indicate malignancy in cystic tumors of the pancreas. Ann Surg 228: 79–86PubMedCrossRefGoogle Scholar
  4. Cherian MG (1994) The significance of the nuclear and cytoplasmic tumor of metallothionein in human liver and tumor cells. Environ Health Perspect 102(suppl 3): 131–135PubMedCrossRefGoogle Scholar
  5. Cherian MG, Apostolova MD (2000) Nuclear localization of metallothionein during cell proliferation and differentiation.. Cell Mol Biol 46: 347–356PubMedGoogle Scholar
  6. Compton CC (2000) Serous cystic tumors of the pancreas.. Semin Diagn Pathol 17: 43–55PubMedGoogle Scholar
  7. Coyle P, Philcox JC, Carey LC et al (2002) Metallothionein: the multipurpose protein. Cell Mol Life Sci 59: 627–647PubMedCrossRefGoogle Scholar
  8. Danielson KG, Ohi S, Huang PC (1982) Immunochemical detection of metallothionein in specific epithelial cells of rat organs. Proc Natl Asad Sci USA 79: 2301–2304CrossRefGoogle Scholar
  9. Davis SR, Cousins RJ (2000) Metallothionein expression in animals: A physiological perspective on function. J Nutr 130: 1085–1088PubMedGoogle Scholar
  10. del Vecchio MT, Pergola L, Tripodi SA et al (2002) Microcystic adenoma associated with a mucinous cystadenocarcinoma: a “collision tumor” of the pancreas. Pancreas 24: 106–108PubMedCrossRefGoogle Scholar
  11. Fan LZ, Cherian MG (2002) Potential role of p53 on metallothionein induction in human epithelial breast cancer cells. Br J Cancer 87: 1019–1026PubMedCrossRefGoogle Scholar
  12. Gerdes B, Wild A, Wittenberg J et al (2003) Tumor-suppressing pathways in cystic pancreatic tumors. Pancreas 26: 42–48PubMedCrossRefGoogle Scholar
  13. Hadama T., Kinoshita M., Kobayashi D et al (2002) Endogenous tumor necrosis factor promotes resistance to cellular stresses by inducing the metallothionein-1A gene. Anticancer Res 22: 4059–4063PubMedGoogle Scholar
  14. Hainaut P, Milner J (1993) A structural role for metal ions in the “wide-type” conformation of the tumour suppressor protein p53. Cancer Res 53: 1739–1742PubMedGoogle Scholar
  15. Ioachim EE, Goussia AC, Agnantis NJ et al (1999) Prognostic evaluation of metallothionein expression in human colorectal neoplasms. J Clin Pathol 52: 876–879PubMedCrossRefGoogle Scholar
  16. Ishikawa T, Nakao A, Nomoto S et al (1998) Immunohistochemical and molecular biological studies of serous cystadenoma of the pancreas. Pancreas 16: 40–44PubMedCrossRefGoogle Scholar
  17. Janssen AM, van Duijn W, Kubben FJ et al (2002) Prognostic significance of metallothionein in human gastrointestinal cancer.. Clin Cancer Res 8: 1889–1896PubMedGoogle Scholar
  18. Joseph MG, Banerjee D, Kocha W et al (2001) Metallothionein expression in patients with small cell carcinoma of the lung. Correlation with other molecular markers and clinical outcome. Cancer 92: 836–842Google Scholar
  19. Kagi JH (1991) Overview of metallothionein. Methods Enzymol 205: 613–626PubMedCrossRefGoogle Scholar
  20. Klassen CD, Liu J, Choudhuri S (1999) Metallothionein: an intracellular protein to protect against cadmium toxicity. Annu Rev Pharmacol Toxicol 39: 267–294CrossRefGoogle Scholar
  21. Klöppel G, Solcia E, Longnecker DS et al (1996) Histological typing of tumours of the exocrine pancreas, second edition.. Springer-Verlag, Berlin-Heidelberg-New York, pp 7–18Google Scholar
  22. Kondo Y, Rusnak JM, Hoyt DG et al (1997) Enhanced apoptosis in metallothionein null cells. Mol Pharmacol 52: 195–201PubMedGoogle Scholar
  23. Madej JA, Milnerowicz H, Dzimira S (1999) Immunohistochemical localization of metallothionein (MT) in epithelial tumors in animals. Med Wet 55: 806–808Google Scholar
  24. Milnerowicz H, Sliwinska-Mosson M, Bizon A et al (2006) Expression of metallothionein and p53 in pancreatic tumors in relation to prognosis. Gut 55: A324Google Scholar
  25. Montag AG, Fossati N, Michelassi F (1990) Pancreatic micro- cystic adenoma coexistent with pancreatic ductal carcinoma: a report of two cases. Am J Surg Pathol 14: 352–355PubMedCrossRefGoogle Scholar
  26. Nath R, Kambadur R, Gulati S et al (1988) Molecular aspects, physiological, functions, and clinical significance of metallothioneins.. Crit Rev Food Sci Nutr 27: 41–85PubMedCrossRefGoogle Scholar
  27. Nitta H, Hirota M, Ohkado A et al (2008) Coexistence of serous cystadenoma and ductal adenocarcinoma in the pancreas: a case report. Pancreas 36: 218–219PubMedCrossRefGoogle Scholar
  28. Ohshio G, Imamura T, Okada N et al (1996) Immunohistochemical study of metallothionein in pancreatic carcinomas.. J Cancer Res Clin Oncol 122: 351–355PubMedCrossRefGoogle Scholar
  29. Oyama T, Take H, Hikino T et al (1996) Immunohistochemical expression of metallothionein in invasive breast cancer in relation to proliferative activity, histology and prognosis. Oncology 53: 112–117PubMedCrossRefGoogle Scholar
  30. Pellegata NS, Sessa F, Renault B et al (1994) K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 54: 1556–1560PubMedGoogle Scholar
  31. Perez-Ordonez B, Nassem A, Lieberman PH et al (1996) Solid serous adenoma of the pancreas: the solid variant of serous cystadenoma. Am J Surg Pathol 20: 1401–1405PubMedCrossRefGoogle Scholar
  32. Pillai G, Roberts H, Gatter K et al (2003) p53 expression in normal paraffin-embedded tissue using different antibodies and antigen retrieval buffer systems. Histopathology 42: 83–87PubMedCrossRefGoogle Scholar
  33. Posniak HV, Olson MC, Demos TC (1991) Coexistent adenocarcinoma and microcystic adenoma of the pancreas. Clin Imaging 15: 220–222PubMedCrossRefGoogle Scholar
  34. Rabczynski J, Milnerowicz H, Sliwinska-Mosson M et al (2006) Hormone-producing serous cystadenoma of the pancreas. Neoplasma 53: 495–499PubMedGoogle Scholar
  35. Saga Y, Hashimoto H, Yachiku S et al (2002) Immunohistochemical expression of metallothionein in human bladder cancer: correlation with histopathological parameters and patient survival. J Urol 168: 2227–2231PubMedCrossRefGoogle Scholar
  36. Santos LD, Chow C, Henderson CJ et al (2002) Serous oligocystic adenoma of the pancreas: a clinicopathological and immunohistochemical study of three cases with ultrastructural findings. Pathology 34: 148–156PubMedCrossRefGoogle Scholar
  37. Satoh K, Shimosegawa T, Moriizumi S et al (1996) K-ras mutation and p53 protein accumulation in intraductal mucin-hypersecreting neoplasms of the pancreas. Pancreas 12: 362–368PubMedCrossRefGoogle Scholar
  38. Schmid KW, Ellis IO, Gee JM et al (1993) Presence and possible significance of immunocytochemically demonstrable metallothionein over-expression in primary invasive ductal carcinoma of the breast. Virchows Arch A Pathol Anat Histopathol 422: 153–159PubMedCrossRefGoogle Scholar
  39. Schwartz D, Rotter V (1998) p53-dependent cell cycle control: response to genotoxic stress. Semin Cancer Biol 8: 325–336PubMedCrossRefGoogle Scholar
  40. Strobel O, Z’graggen K, Schmitz-Winnenthal FH et al (2003) Risk of malignancy in serous cystic neoplasms of the pancreas. Digestion 68: 24–33PubMedCrossRefGoogle Scholar
  41. Symonds H, Krall L, Remington L et al (1994) p53-dependent apoptosis suppresses tumor-growth and progression in-vivo. Cell 78: 703–711PubMedCrossRefGoogle Scholar
  42. Tekada A, Hisada H, Okada S et al (1997) Tumor cell growth is inhibited by suppressing metallothionein-I synthesis. Cancer Lett 116: 145–149CrossRefGoogle Scholar
  43. Tomita T (2000a) Metallothionein in pancreatic endocrine neoplasms. Mod Pathol 13: 389–395PubMedCrossRefGoogle Scholar
  44. Tomita T (2000b) New markers for pancreatic islets and islet cell tumors. Pathol Int 52: 425–432CrossRefGoogle Scholar
  45. Zelger B, Hittmair A, Schir M et al (1993) Immunohistochemically demonstrated metallothionein expression in malignant melanoma. Histopathology 23: 257–263PubMedCrossRefGoogle Scholar
  46. Zeng J, Heuchel R, Schaffner W et al (1991) Thionein (apometallothionein) can modulate DNA binding and transcription activation by zinc finger containing factor Sp1. FEBS Lett 279: 310–312PubMedCrossRefGoogle Scholar

Copyright information

© L. Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland 2009

Authors and Affiliations

  • Mariola Śliwińska-Mossoń
    • 1
  • Halina Milnerowicz
    • 1
  • Jerzy Rabczyński
    • 2
  • Stanisław Milnerowicz
    • 3
  1. 1.Department of Biomedical and Environmental AnalysesWrocław Medical UniversityWrocławPoland
  2. 2.Department of Pathological AnatomyWrocław Medical UniversityWrocławPoland
  3. 3.Department and Clinic of Gastrointestinal and General SurgeryWrocław Medical UniversityWrocławPoland

Personalised recommendations